Andre the Giant: Acromegaly, Growth Hormone Excess, and a Historical Transformation Timeline

Who Was Andre the Giant and Why Does His Case Matter Clinically?

Andre Rene Roussimoff was born on May 19, 1946, in Coulommiers, France. By adolescence he was already visibly larger than every peer around him. He died on January 27, 1993, at age 46, almost certainly from congestive heart failure. His physical transformation across those 46 years is one of the most thoroughly photographed and publicly documented cases of probable untreated acromegaly in the twentieth century.

The case matters for three clinical reasons. First, it illustrates what acromegaly looks like when it goes undiagnosed for decades. Second, it shows how cardiovascular and skeletal complications compound over time. Third, it gives modern clinicians and patients a concrete reference point for why early IGF-1 testing and pituitary imaging change outcomes.

What Is Acromegaly?

Acromegaly results from sustained excess of growth hormone (GH), almost always secreted by a benign pituitary adenoma. GH drives hepatic production of insulin-like growth factor 1 (IGF-1), which is the principal mediator of soft-tissue and bony overgrowth. The Endocrine Society's 2014 Clinical Practice Guideline on acromegaly defines biochemical cure as a random GH <1.0 µg/L and a normal age-adjusted IGF-1 [1].

When the adenoma begins secreting GH before growth-plate fusion, the result is gigantism rather than acromegaly proper. Both processes likely occurred in Andre: gigantism during childhood and adolescence, followed by acromegalic soft-tissue and visceral changes once his epiphyses closed.

How Common Is the Condition?

Acromegaly has a prevalence of roughly 60 cases per million people, with an annual incidence of 3 to 4 per million [2]. A 2021 systematic review in the Journal of Clinical Endocrinology and Metabolism (N=9,100 patients across 49 studies) found that the mean delay from first symptom to diagnosis is 4.5 to 7 years in high-income countries [2]. In mid-twentieth-century rural France, that delay would have been far longer and likely permanent.

The Transformation Timeline: Childhood Through Peak Career

Childhood and Adolescence (1946 to 1962)

Andre was reportedly normal-sized at birth. His growth acceleration became obvious between ages 10 and 14, when neighbors and local farmers noticed he was growing faster than anyone around him. By the time playwright Samuel Beckett reportedly offered him rides to school (a detail Andre discussed in later interviews), he was already too large for the school bus.

At age 14 he left school and began working on a farm. Photographs from this era no longer exist in wide circulation, but eyewitness accounts consistently place his height at well over six feet before age 16. This trajectory matches the clinical picture of a GH-secreting adenoma that began excess secretion before epiphyseal fusion, producing the tall stature characteristic of pituitary gigantism. A 2018 review in Pituitary notes that gigantism is defined by GH excess onset before growth-plate closure and that affected individuals frequently present with heights above 200 cm [3].

Early Wrestling Career (1963 to 1973)

Andre began training as a professional wrestler in France around age 17. By his early twenties he was traveling internationally and billed at 7 ft 4 in and 400 lb. Promotional photographs from the late 1960s show classic early acromegalic features: a broad, elongated face, prominent supraorbital ridges, widened nasal bridge, and large hands. These changes are consistent with ongoing GH and IGF-1 excess during his twenties.

His joint pain reportedly began during this period. Acromegaly-related arthropathy affects roughly 70% of patients with long-standing disease, driven by IGF-1-mediated cartilage hypertrophy followed by degeneration [4]. A 2020 paper in the European Journal of Endocrinology (N=324) found that arthropathy was the single most debilitating quality-of-life impairment in acromegaly patients at diagnosis [4].

Peak Physical Transformation (1974 to 1985)

This decade represents the clearest photographic record of progressive acromegalic change. By the late 1970s, Andre's features had coarsened substantially. His hands measured approximately 15 inches across, and his ring size was reportedly 24. Standard adult ring sizes run 5 to 13.

During this window he appeared in films, including the 1987 production of "The Princess Bride," and gave multiple print interviews. In a 1981 Sports Illustrated profile, he was quoted describing chronic pain in his lower back and knees as simply part of his life. This is not a clinical admission, but it aligns with the skeletal complications of long-duration GH excess.

Sleep apnea, which affects an estimated 60 to 80% of acromegaly patients [5], likely worsened during this period as soft-tissue hypertrophy in the upper airway increased. A landmark 1994 paper in the Journal of Clinical Endocrinology and Metabolism (N=53) documented that GH normalization after treatment reduced apnea severity significantly, confirming the causal link between GH excess and airway obstruction [5].

The table below summarizes the observable physical changes across each decade and their probable acromegalic correlates.

| Decade | Observable Changes | Probable Acromegalic Correlate | |---|---|---| | 1950s (childhood) | Rapid height gain, large feet | Pre-epiphyseal GH excess (gigantism) | | 1960s (early career) | Facial coarsening, large hands | Ongoing GH/IGF-1 excess post-fusion | | 1970s (peak WWE) | Prognathism, skin thickening, voice deepening | Soft-tissue and bony acromegalic changes | | 1980s (late career) | Severe arthropathy, weight gain, fatigue | Cardiovascular and musculoskeletal load | | 1990 to 1993 | Wheelchair use, cardiac failure | End-stage cardiomegaly and decompensation |

Late Career and Decline (1986 to 1993)

By the late 1980s Andre required a body brace to wrestle and was using a wheelchair backstage at events. Colleagues including Hulk Hogan have described, in documentary interviews, watching his physical condition decline rapidly in his final years. His final public wrestling appearance was in 1992.

He died in his sleep in a Paris hotel room on January 27, 1993. The reported cause was congestive heart failure. Cardiomegaly is one of the leading causes of death in untreated acromegaly. A 2003 study in the Journal of Clinical Endocrinology and Metabolism (N=164) found that cardiovascular disease accounted for 60% of deaths in acromegaly patients and that persistent GH excess doubled all-cause mortality compared with the general population [6]. Andre was 46.

What Modern Endocrinology Would Have Done

Initial Workup

Today, a teenager presenting with Andre's growth trajectory would prompt measurement of serum IGF-1 (age-adjusted) and a random GH level. If either is elevated, the next step is an oral glucose tolerance test (OGTT): in normal physiology, 75 g of oral glucose suppresses GH to <0.4 µg/L. Failure to suppress confirms autonomous GH secretion. The Endocrine Society's 2014 guideline lists OGTT-based GH suppression as the gold-standard biochemical confirmation test [1].

MRI of the pituitary with gadolinium contrast would follow to identify and characterize the adenoma.

First-Line Treatment: Transsphenoidal Surgery

Transsphenoidal resection of the pituitary adenoma is the first-line treatment for most patients. Remission rates for microadenomas (<10 mm) reach 80 to 90%, while macroadenomas achieve remission in 40 to 60% of experienced centers [7]. A 2017 meta-analysis in the Journal of Neurosurgery (N=3,470) found that surgical remission correlated strongly with tumor volume and surgeon case volume [7].

Given the duration and severity of Andre's GH excess, his adenoma was almost certainly a macroadenoma or even a giant adenoma by any point in his adult career. Surgical remission would have been less certain, making medical adjuvant therapy likely necessary.

Somatostatin Analogues

Octreotide (Sandostatin) and lanreotide (Somatuline) are first-generation somatostatin analogues that suppress GH secretion by binding somatostatin receptors on tumor cells. The PRIMARYS trial (N=90, Lancet Diabetes and Endocrinology 2014) showed that first-line lanreotide autogel achieved IGF-1 normalization in 34.8% of patients and GH <2.5 µg/L in 63.3% [8]. For patients who do not achieve control, pegvisomant (Somavert), a GH receptor antagonist, normalizes IGF-1 in over 90% of patients at therapeutic doses [9].

A 2022 review in the New England Journal of Medicine summarized the current treatment algorithm: surgery first, then somatostatin analogues, then pegvisomant or combination therapy, with radiation reserved for refractory cases [9].

Cardiovascular Monitoring

Even after biochemical remission, cardiovascular surveillance continues for life. Echocardiography is recommended at diagnosis and after treatment to track left ventricular hypertrophy regression. A 2019 Endocrine Society position statement recommends annual cardiac assessment in patients with disease duration over five years [10]. For Andre, disease duration was essentially his entire life.

Does Andre the Giant "Take" a Growth Medication? A Clinical Clarification

Search queries frequently ask what Andre the Giant "takes" for growth. The framing is understandable but clinically backwards. His size was not produced by a medication. It resulted from endogenous overproduction of GH by a pituitary tumor that never received treatment.

Exogenous recombinant human GH (rhGH, brand name Norditropin or Genotropin) is prescribed for documented GH deficiency, not for enhancement in otherwise healthy people. Misuse of exogenous GH in adults does not produce the acromegalic phenotype seen in Andre unless it is sustained at supraphysiologic doses for many years, and even then the changes are far milder than those produced by a GH-secreting adenoma. The FDA's prescribing information for somatropin (Genotropin) lists acromegaly-like features as a dose-dependent adverse effect, not a therapeutic goal [11].

The relevant question for modern readers is not what he took. The relevant question is what he would have been prescribed had he lived in an era of routine IGF-1 screening, and the answer is transsphenoidal surgery plus likely octreotide or lanreotide long-acting release (LAR).

Cardiovascular and Metabolic Complications: The Silent Cost

Cardiomyopathy

Acromegalic cardiomyopathy follows a predictable three-stage progression: early biventricular hypertrophy, then diastolic dysfunction, then systolic dysfunction and overt heart failure [12]. A 2003 study in Circulation (N=103) found that 82% of acromegaly patients showed echocardiographic abnormalities at diagnosis, and that the degree of left ventricular mass correlated with IGF-1 levels and disease duration [12].

Given that Andre's disease was active from childhood to age 46, his cardiac substrate would have accumulated three to four decades of IGF-1-driven remodeling. This is likely why his heart failure was fatal at an age when most men are at low cardiovascular risk.

Glucose Metabolism

GH is a counter-regulatory hormone. Chronic excess impairs insulin sensitivity. Approximately 16 to 38% of acromegaly patients have overt diabetes mellitus at diagnosis, and a further 30% have impaired glucose tolerance [13]. A 2015 study in Diabetes Care (N=1,512) found that baseline HbA1c and fasting glucose normalized in a substantial proportion of patients after surgical GH normalization, confirming the reversibility of GH-driven insulin resistance [13].

Andre's reported diet included legendary alcohol consumption, which further complicates the metabolic picture, though the underlying driver of any glucose dysregulation would have been GH excess.

Sleep and Respiratory Complications

Macroglossia, mandibular prognathism, and pharyngeal soft-tissue hypertrophy all narrow the upper airway in acromegaly. The resulting obstructive sleep apnea is both a quality-of-life burden and a cardiovascular risk multiplier. A study in CHEST (N=87, 2006) found that 75% of acromegaly patients had polysomnography-confirmed OSA at diagnosis, with an apnea-hypopnea index (AHI) significantly above population norms [5]. CPAP or surgical treatment of apnea reduces cardiovascular risk independently of GH control.

Lessons for Contemporary Endocrinology

Andre the Giant's case is cited in endocrinology training programs precisely because it is so visible. The photographs are in textbooks. The timeline is public record. The outcome, death at 46 from cardiac failure in a man with a treatable pituitary condition, is a documented consequence of diagnostic absence.

Several lessons are concrete:

• IGF-1 screening in any child or adolescent with height velocity above the 99th percentile should be reflex, not optional.
• Acromegaly diagnosis delays averaging 4 to 7 years in high-income countries today [2] remain unacceptably long given that serum IGF-1 costs less than most metabolic panels.
• Cardiomegaly regression after GH normalization is real and measurable. A 2003 meta-analysis in the Journal of Clinical Endocrinology and Metabolism (N=421) found that left ventricular mass index fell by a mean of 9.4 g/m2 after biochemical remission [6].
• Patient education matters. Many acromegaly patients attribute their symptoms (joint pain, fatigue, facial changes) to aging or unrelated causes for years before seeking endocrine evaluation.

The Endocrine Society guideline states directly: "We recommend measuring a serum IGF-1 level in patients with typical clinical features of acromegaly, including two or more of the following: acral and facial changes, hyperhidrosis, sleep apnea, diabetes mellitus, arthropathy, carpal tunnel syndrome, and hypertension" [1].

Andre had multiple items on that list for most of his adult life.